Verstraete M, Vermylen J, Schetz J
Thromb Haemost. 1978 Feb 28;39(1):61-8.
An intermittent dosage scheme of streptokinase (standard initial dose 600,000 units SK infused over 30 min and repeated injections of 250,000 units SK at 24 hr intervals) was applied during 4 days in 9 patients with chronic obliterative arterial disease and in 8 patients with venous occlusion. Each dose of streptokinase produced an immediate fall in plasminogen to 17% (SEM 5.1) of the initial value, the level then rose to 50% (SEM 5.4) within 24 hr. Lowered levels of antiplasmin and fibrinogen (both less than 40% of the initial values) were maintained. This safe level of fibrinogen was maintained despite brief but high peaks of plasmin activity after each injection of SK. A parallel increase of the thrombin time and the fibrin (ogen) degradation products was obtained following each infusion. No bleeding was observed. The relative therapeutic effect of intermittent infusions of streptokinase has still to be compared with the continuous administration of streptokinase in controlled clinical trials.
对9例慢性闭塞性动脉疾病患者和8例静脉闭塞患者，应用链激酶间歇给药方案（标准初始剂量为60万单位链激酶，30分钟内输注完毕，之后每隔24小时重复注射25万单位链激酶），持续4天。每次注射链激酶后，纤溶酶原立即降至初始值的17%（标准误5.1），随后在24小时内升至50%（标准误5.4）。抗纤溶酶和纤维蛋白原水平降低（均低于初始值的40%）并维持在该水平。尽管每次注射链激酶后纤溶酶活性会出现短暂但很高的峰值，但纤维蛋白原仍维持在这一安全水平。每次输注后，凝血酶时间和纤维蛋白（原）降解产物均呈平行增加。未观察到出血现象。在对照临床试验中，链激酶间歇输注的相对治疗效果仍有待与链激酶持续给药进行比较。
